Ocugen signs subscription agreement to invest $5M in Carisma as part of Merger concurrent financing

Ocugen, Inc.

Ocugen committed to purchase $5.0M of Carisma common stock at a price per share determined by formula per Merger Agreement.
Investment is part of a Concurrent Investment targeting aggregate gross proceeds of at least $25M from multiple investors.
Subscription Agreement includes MFN clause: if other investors get better terms, Ocugen automatically receives them.
Closing expected at or immediately after Merger closing, subject to customary conditions.
Carisma intends to enter Registration Rights Agreement with Investors, including Ocugen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.